Pluristyx, Inc. entered into an agreement with the Advanced Regenerative Manufacturing Institute BioFab USA to manufacture and commercialize Pluristyx’s clinical grade reprogrammed induced Pluripotent Stem Cells (iPSCs). The collaboration will make it possible to accelerate the scalable, consistent, and cost-effective manufacturing of stem cell derived products for patient administration. The agreement provides ARMI BioFab USA, its affiliates, and Members streamlined access to high-quality cl...